Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osteodex in Metastatic CRPC
NCT02378870Phase 2Terminated
- Sponsor
- DexTech Medical
- Start
- Jan 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Osteodex with Placebo (2 arms). Primary endpoints: Bone Alkaline Phosphatase at 24 weeks and Serum Procollagen type 1 N-terminal propeptide at 24 weeks. Started Jan 2015; status: terminated.
02
Drugs
OsteoDex
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02378870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02378870.